Zai Lab (ZLAB) to Release Quarterly Earnings on Tuesday

Zai Lab (NASDAQ:ZLAB) will be issuing its quarterly earnings data after the market closes on Tuesday, August 6th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Zai Lab (NASDAQ:ZLAB) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.38. The firm had revenue of $87.15 million for the quarter, compared to analysts’ expectations of $77.07 million. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. During the same period in the prior year, the company earned ($0.51) EPS. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Trading Down 1.2 %

Shares of NASDAQ ZLAB opened at $18.21 on Monday. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -5.22 and a beta of 1.06. Zai Lab has a 52 week low of $13.48 and a 52 week high of $31.22. The company’s 50-day moving average price is $18.44 and its 200 day moving average price is $18.58.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ZLAB shares. JPMorgan Chase & Co. decreased their price target on shares of Zai Lab from $43.00 to $38.00 and set an “overweight” rating on the stock in a research note on Friday, July 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a research report on Monday, July 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zai Lab currently has an average rating of “Buy” and an average target price of $58.97.

Insider Activity

In other news, CEO Ying Du sold 23,939 shares of Zai Lab stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $17.90, for a total transaction of $428,508.10. Following the sale, the chief executive officer now owns 1,142,833 shares in the company, valued at $20,456,710.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Ying Du sold 23,939 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $17.90, for a total transaction of $428,508.10. Following the completion of the sale, the chief executive officer now owns 1,142,833 shares of the company’s stock, valued at $20,456,710.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Yajing Chen sold 2,154 shares of the firm’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $17.90, for a total transaction of $38,556.60. Following the sale, the chief financial officer now directly owns 13,714 shares of the company’s stock, valued at approximately $245,480.60. The disclosure for this sale can be found here. Insiders have sold 60,934 shares of company stock worth $1,116,043 over the last 90 days. Company insiders own 5.23% of the company’s stock.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.